Lifepoint announces new chief diversity officer
Marsh assumed her new role on Dec. 5, and will be responsible for developing and implementing diversity, equity and inclusion initiatives, according to a release.
CMS estimates 41.5M people affected by innovation center models since late 2020
The Center for Medicare and Medicaid Innovation is currently operating 33 models studying potential improvements in healthcare payment and delivery.
Trinity Health to build $238M hospital outside Detroit
The nonprofit system plans to expand its medical center campus in suburban Detroit amid a challenging operating environment for many providers.
Nonprofit hospitals’ staffing challenges easing, Fitch says
However, the ongoing pandemic, influenza and RSV cases are causing capacity issues that pose a major near-term risk to labor costs, according to the report.
Maternal health services suffer in states with abortion bans, report finds
States risk driving away healthcare providers who are reluctant to work where their practices will be restricted, according to a Commonwealth Fund analysis.
HHS examines automation’s role in healthcare cybersecurity
The Office of Information Security outlined ways that hackers are using artificial intelligence and machine learning to build more effective malware.
CMS tackles provider availability, exchange regulations in proposed rule
The regulation comes as the ACA exchanges, spurred by financial incentives during the COVID-19 pandemic, reached record enrollment numbers.
Bright Health in danger of being booted from NYSE
The insurtech, which went public last year, has struggled with medical costs during the pandemic and has shrunk its business over the past year.
COVID-19 vaccine saved millions of lives, study calculates
The vaccines also reduced infections and hospitalizations, which freed up hospital resources, researchers at the Commonwealth Fund and Yale School of Public Health concluded.
Amgen to buy Horizon Therapeutics in year’s biggest biotech deal
After outlasting rival suitors Sanofi and J&J in deal talks, Amgen agreed to a deal that values the Ireland-based maker of rare and inflammatory disease drugs at about $28 billion.